Global Personalized Medicine Biomarkers Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Personalized Medicine Biomarkers Market is presumed to reach the market size of nearly USD 175.46 BN by 2030 from USD 24.92 BN in 2022 with a CAGR of 27.63% under the study period 2023 - 2030.

Personalised medicine biomarkers are the use of biomarkers for developing personalised medicines for patients. It assists in making treatment decisions, improving treatment outcomes and creating safe therapies for patients. It also helps predict the occurrence of health issues and dose selection due to their prognostic utility. Biomarker helps in the early detection of diseases, increase the chance of patient survival, and reduce treatment cost.

Market Dynamics:

The personalised medicine biomarkers market growth is witnessing an upward trend due to the rising prevalence of chronic diseases all over the globe. The advancement in diagnosis and detection of chronic diseases, coupled with the growing demand for personalised medicines, are contributing to the growth of this market. Increasing awareness regarding the importance of predicting prognosis is surging the demand for the personalised medicine biomarkers market. In addition, different advantages of personalised medicine biomarkers, such as early detection of diseases and reduction in the cost of treatment, are propelling the demand for this market. Furthermore, continuous advancement in the development of biomarkers is expected to boost the growth of personalised medicine biomarkers in the market over the forecast period.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of personalized medicine biomarkers. The growth and trends of personalized medicine biomarkers industry provide a holistic approach to this study.

Market Segmentation:

This section of the personalized medicine biomarkers market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

By Indication

Oncology (Type, Circulating Biomarkers)
Neurology
Diabetes
Autoimmune Diseases
Cardiology
Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Personalized Medicine Biomarkers market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the personalized medicine biomarkers market include Laboratory Corporation of America Holding, Quest Diagnostics Incorporated, Agilent Technologies Inc., Genome Medical Inc., Coriell Life Sciences., Thermo Fisher Scientific Inc., NeoGenomics Laboratories, Foundation Medicine Inc, Illumina Inc., Guardant Health. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

Product Code: VMR112110341

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PERSONALIZED MEDICINE BIOMARKERS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Early Detection/Screening Historic and Forecast Sales by Regions
6.5 Diagnosis Historic and Forecast Sales by Regions
6.6 Treatment Selection Historic and Forecast Sales by Regions
6.7 Monitoring Historic and Forecast Sales by Regions

7 . GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Oncology (Type, Circulating Biomarkers) Historic and Forecast Sales by Regions
7.5 Neurology Historic and Forecast Sales by Regions
7.6 Diabetes Historic and Forecast Sales by Regions
7.7 Autoimmune Diseases Historic and Forecast Sales by Regions
7.8 Cardiology Historic and Forecast Sales by Regions
7.9 Others Historic and Forecast Sales by Regions

8 . GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE PERSONALIZED MEDICINE BIOMARKERS COMPANIES

9.1. Personalized Medicine Biomarkers Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF PERSONALIZED MEDICINE BIOMARKERS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Laboratory Corporation of America Holding
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Quest Diagnostics Incorporated
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Agilent Technologies Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Genome Medical Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Coriell Life Sciences.
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Thermo Fisher Scientific Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. NeoGenomics Laboratories
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Foundation Medicine Inc
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Illumina Inc.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Guardant Health
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies